HC Wainwright Has Negative Outlook of SABS FY2024 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Equities research analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of SAB Biotherapeutics in a research note issued on Thursday, November 7th. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($3.75) for the year, down from their prior forecast of ($3.64). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.59) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q4 2024 earnings at ($1.30) EPS, FY2025 earnings at ($5.27) EPS and FY2026 earnings at ($4.01) EPS.

Several other analysts have also recently weighed in on SABS. Chardan Capital reiterated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a report on Thursday. Craig Hallum initiated coverage on shares of SAB Biotherapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $11.00 target price on the stock. Finally, Oppenheimer reiterated an “outperform” rating and set a $12.00 price target on shares of SAB Biotherapeutics in a research report on Thursday, September 12th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, SAB Biotherapeutics currently has an average rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Price Performance

SABS opened at $3.51 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.24 and a quick ratio of 5.24. The stock’s 50 day moving average price is $2.90 and its 200-day moving average price is $3.00. SAB Biotherapeutics has a 52-week low of $2.16 and a 52-week high of $9.72.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 87.49%.

Institutional Investors Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. First PREMIER Bank purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned approximately 0.21% of SAB Biotherapeutics at the end of the most recent reporting period. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.